Investor Relations

Latest Financial Results

Latest Annual Filing

For Fiscal Year Ending Dec 31, 2019

Company Overview

Sutro Biopharma, located in South San Francisco, is a clinical-stage drug discovery, development and manufacturing company creating a broad variety of next-generation protein therapeutics for oncology based on its proprietary, cell-free protein synthesis platform, XpressCF.

Sutro is dedicated to transforming the lives of cancer patients by creating medicines with improved therapeutic profiles for areas of unmet need.

Sutro designs cytokine-based immuno-oncology therapies, antibody-drug conjugates, and bispecific antibodies primarily directed at clinically-validated targets for which the current standard of care is suboptimal.

Sutro's platform allows it to accelerate discovery and development of first-in-class and best-in-class molecules through rapid and systematic evaluation of protein structure-activity relationships to create optimized homogeneous product candidates.

Investor Contact Information


Sutro Biopharma, Inc.
310 Utah Avenue
Suite 150
South San Francisco, CA 94080

Investor Relations

Solebury Trout
John Graziano
T: 646-378-2942

Solebury Trout
Xuan Yang
T: 646-378-2975


Russo Partners
David Schull
T: (212) 845-4271

Russo Partners
Maggie Beller
T: (646) 942-5631